Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-94d59 Total loading time: 0 Render date: 2024-03-29T04:06:53.650Z Has data issue: false hasContentIssue false

39 - Breast Metastasis

from PART II - CLINICAL RESEARCH

Published online by Cambridge University Press:  05 June 2012

Patrick G. Morris
Affiliation:
Memorial Sloan-Kettering Cancer Center, United States
Heather L. McArthur
Affiliation:
Memorial Sloan-Kettering Cancer Center, United States
Clifford A. Hudis
Affiliation:
Memorial Sloan-Kettering Cancer Center, United States
David Lyden
Affiliation:
Weill Cornell Medical College, New York
Danny R. Welch
Affiliation:
Weill Cornell Medical College, New York
Bethan Psaila
Affiliation:
Imperial College of Medicine, London
Get access

Summary

PATTERNS OF METASTATIC SPREAD

Background

Breast cancer is an important public health problem, with more than one million new cases worldwide annually. In the developed world, early-stage disease represents an increasing proportion of incident breast cancer diagnoses, whereas metastatic breast cancer (MBC) without a preceding diagnosis of early-stage disease is a rare event. However, despite an early-stage diagnosis, up to one-third of patients will experience distant relapse. MBC is treatable but incurable, with a median survival of two to three years. Consequently, clinicians often recommend systemic adjuvant therapy for patients with early breast cancer (EBC), as it prevents or delays the development of incurable metastatic disease. Adjuvant therapy may comprise hormonal therapy, cytotoxic chemotherapy, and targeted therapy, depending on the breast cancer subtype, the individual's risk of recurrence, and various patient-specific factors including age, menopausal status, and comorbid conditions.

Breast cancer is a heterogenous disease with respect to natural history and response to therapy. More than 95 percent of breast cancers arise from the breast epithelium and are carcinomas. The two most common histological subtypes are invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), which account for approximately 75 percent and 15 percent of breast cancers, respectively. IDC cells are typically clustered in well-formed glandular structures, whereas ILC cells are frequently organized in single file. These distinct cellular patterns are commonly used to distinguish the two histologic subtypes.

Type
Chapter
Information
Cancer Metastasis
Biologic Basis and Therapeutics
, pp. 425 - 439
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Stewart, BW, Kleihues, P (2003) World Cancer Report. Lyon, France: IARC Press.Google Scholar
Li, CI, Uribe, DJ, Daling, JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 93: 1046–52.CrossRefGoogle ScholarPubMed
Nadji, M, Gomez-Fernandez, C, Ganjei-Azar, P et al. (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 123: 21–7.CrossRefGoogle ScholarPubMed
Diab, SG, Elledge, RM, Clark, GM (2000) Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 92: 550–6.CrossRefGoogle ScholarPubMed
Li, CI, Daling, JR, Malone, KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 21: 28–34.CrossRefGoogle ScholarPubMed
Anderson, GL, Limacher, M, Assaf, AR et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 291: 1701–12.Google ScholarPubMed
Allred, DC, Bustamante, MA, Daniel, CO et al. (1990) Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg. 125: 107–13.CrossRefGoogle ScholarPubMed
Schnitt, SJ (2006) Estrogen receptor testing of breast cancer in current clinical practice: what's the question? J Clin Oncol. 24: 1797–9.CrossRefGoogle ScholarPubMed
Collins, LC, Botero, ML, Schnitt, SJ (2005) Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 123: 16–20.CrossRefGoogle ScholarPubMed
Eifel, P, Axelson, JA, Costa, J et al. (2001) National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 93: 979–89.Google ScholarPubMed
Harris, L, Fritsche, H, Mennel, R et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25: 5287–312.CrossRefGoogle Scholar
Hudis, CA (2007) Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med. 357: 39–51.CrossRefGoogle ScholarPubMed
Wolff, AC, Hammond, ME, Schwartz, JN et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 25: 118–45.CrossRefGoogle Scholar
McArthur, H, Tan, L, Patil, S et al. (2008) High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 co-amplification is uncommon in human breast cancer. San Antonio Breast Cancer Symposium Abstract 2023.
Perou, CM, Sorlie, T, Eisen, MB et al. (2000) Molecular portraits of human breast tumours. Nature. 406: 747–52.CrossRefGoogle ScholarPubMed
Sorlie, T, Perou, CM, Tibshirani, R et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98: 10869–74.CrossRefGoogle ScholarPubMed
,EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. an overview of the randomised trials. Lancet. 365: 1687–717.CrossRefGoogle Scholar
Joensuu, H, Kellokumpu-Lehtinen, PL, Bono, P et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 354: 809–20.CrossRefGoogle ScholarPubMed
Piccart-Gebhart, MJ, Procter, M, Leyland-Jones, B et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 353: 1659–72.CrossRefGoogle ScholarPubMed
Romond, EH, Perez, EA, Bryant, J, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353: 1673–84.CrossRefGoogle ScholarPubMed
Slamon, D, Eiermann, W, Robert, N et al. (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium: Abstract #1.
Nguyen, DX, Massague, J (2007) Genetic determinants of cancer metastasis. Nat Rev Genet. 8: 341–52.CrossRefGoogle ScholarPubMed
Paget, S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8: 98–101.Google ScholarPubMed
Gupta, GP, Minn, AJ, Kang, Y et al. (2005) Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol. 70: 149–58.CrossRefGoogle ScholarPubMed
Ferlicot, S, Vincent-Salomon, A, Medioni, J et al. (2004) Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer. 40: 336–41.CrossRefGoogle ScholarPubMed
Yang, J, Mani, SA, Donaher, JL et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117: 927–39.CrossRefGoogle ScholarPubMed
Holdaway, IM, Bowditch, JV (1983) Variation in receptor status between primary and metastatic breast cancer. Cancer. 52: 479–85.3.0.CO;2-O>CrossRefGoogle ScholarPubMed
Kuukasjarvi, T, Kononen, J, Helin, H et al. (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 14: 2584–9.CrossRefGoogle ScholarPubMed
Vijver, MJ, He, YD, van't Veer, LJ et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347: 1999–2009.CrossRefGoogle ScholarPubMed
Paik, S, Shak, S, Tang, G et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 351: 2817–26.CrossRefGoogle ScholarPubMed
Paik, S, Tang, G, Shak, S et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 24: 3726–34.CrossRefGoogle ScholarPubMed
,NCCN (2008) NCCN Practice Guidelines in Oncology v.2.2008.
Quon, A, Gambhir, SS (2005) FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol. 23: 1664–73.CrossRefGoogle ScholarPubMed
Eubank, WB, Mankoff, DA (2005) Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med. 35:84–99.CrossRefGoogle ScholarPubMed
Avril, N, Rose, CA, Schelling, M et al. (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 18: 3495–502.CrossRefGoogle ScholarPubMed
Crippa, F, Seregni, E, Agresti, R et al. (1998) Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 25: 1429–34.CrossRefGoogle ScholarPubMed
Fletcher, RH (1986) Carcinoembryonic antigen. Ann Intern Med. 104: 66–73.CrossRefGoogle ScholarPubMed
Kiang, DT, Greenberg, LJ, Kennedy, BJ (1990) Tumor marker kinetics in the monitoring of breast cancer. Cancer. 65: 193–9.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
Ashworth, T (1869) A case of cancer in which cells to those in the tumors were seen in the blood after death. Aust Med J. 14: 146–9.Google Scholar
Bertazza, L, Mocellin, S, Nitti, D (2008) Circulating tumor cells in solid cancer: tumor marker of clinical relevance? Curr Oncol Rep. 10: 137–46.CrossRefGoogle ScholarPubMed
Dawood, S, Cristofanilli, M (2007) Integrating circulating tumor cell assays into the management of breast cancer. Curr Treat Options Oncol. 8: 89–95.CrossRefGoogle ScholarPubMed
Hayes, DF, Cristofanilli, M, Budd, GT et al. (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 12: 4218–24.CrossRefGoogle ScholarPubMed
Cristofanilli, M, Budd, GT, Ellis, MJ et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351: 781–91.CrossRefGoogle ScholarPubMed
Di Leo, A, Moretti, E (2008) Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. J Clin Oncol. 26: 5011–3.CrossRefGoogle ScholarPubMed
McArthur, HL, Hudis, CA (2007) Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data. Clin Breast Cancer. 8 Suppl 1: S6-S10.CrossRefGoogle ScholarPubMed
Sunderland, MC, Osborne, CK (1991) Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 9: 1283–97.CrossRefGoogle ScholarPubMed
Klijn, JG, Beex, LV, Mauriac, L et al. (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 92: 903–11.CrossRefGoogle ScholarPubMed
Ingle, JN, Krook, JE, Green, SJ et al. (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol. 4: 178–85.CrossRefGoogle ScholarPubMed
Buchanan, RB, Blamey, RW, Durrant, KR et al. (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 4: 1326–30.CrossRefGoogle ScholarPubMed
Jonat, W, Kaufmann, M, Blamey, RW et al. (1995) A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer. 31A: 137–42.CrossRefGoogle ScholarPubMed
Boccardo, F, Rubagotti, A, Perrotta, A et al. (1994) Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol. 5: 337–42.CrossRefGoogle ScholarPubMed
Paridaens, RJ, Dirix, LY, Beex, LV et al. (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 15: 15.Google Scholar
Mouridsen, H, Gershanovich, M, Sun, Y et al. (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 21: 2101–9.CrossRefGoogle ScholarPubMed
Bonneterre, J, Buzdar, A, Nabholtz, JM et al. (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 92: 2247–58.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed
Chia, S, Gradishar, W, Mauriac, L et al. (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 26: 1664–70.CrossRefGoogle ScholarPubMed
Howell, A, Robertson, JF, Abram, P et al. (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 22: 1605–13.CrossRefGoogle ScholarPubMed
Pyrhonen, S, Valavaara, R, Modig, H et al. (1997) Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the ‘nordic’ Phase III study. Br J Cancer. 76: 270–7.CrossRefGoogle ScholarPubMed
Hayes, DF, Zyl, JA, Hacking, A et al. (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 13: 2556–66.CrossRefGoogle ScholarPubMed
Veelen, H, Willemse, PH, Tjabbes, T et al. (1986) Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer. 58: 7–13.3.0.CO;2-#>CrossRefGoogle ScholarPubMed
Muss, HB, Case, LD, Atkins, JN et al. (1994) Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol. 12: 1630–8.CrossRefGoogle ScholarPubMed
Smith, IE, Walsh, G, Skene, A et al. (2007) A Phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 25: 3816–22.CrossRefGoogle ScholarPubMed
Hoadley, KA, Weigman, VJ, Fan, C et al. (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 8: 258.CrossRefGoogle ScholarPubMed
Dickler, MN, Cobleigh, MA, Miller, KD et al. (2008) Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 22: 22.Google Scholar
Modi, S, D'Andrea, G, Norton, L et al. (2006) A Phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer. 7: 270–7.CrossRefGoogle ScholarPubMed
Carey, L, Rugo, H, Marcom, P et al. (2008) TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol. 26: No 15S Abstract 1009.CrossRefGoogle Scholar
O'Shaughnessy, J, Weckstein, D, Vukelja, S et al. (2007) Preliminary results of a randomized Phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. San Antonio Breast Cancer Symposium: Abstract 308.
Cristofanilli, M, Valero, V, Mangalik, A (2008) A Phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol. 26: Abstract 1012.CrossRefGoogle Scholar
Cobleigh, MA, Vogel, CL, Tripathy, D et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17: 2639–48.CrossRefGoogle ScholarPubMed
Mass, R, Press, M, Anderson, S (2001) Improved survival benefit from herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol. 20: Abstract 85.Google Scholar
Seidman, AD, Berry, D, Cirrincione, C et al. (2008) Randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 26: 1642–9.CrossRefGoogle ScholarPubMed
Bartsch, R, Wenzel, C, Altorjai, G et al. (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 25: 3853–8.CrossRefGoogle ScholarPubMed
Bartsch, R, Wenzel, C, Gampenrieder, SP et al. (2008) Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 62: 903–10.CrossRefGoogle ScholarPubMed
Burstein, HJ, Keshaviah, A, Baron, AD et al. (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 110: 965–72.CrossRefGoogle ScholarPubMed
Marty, M, Cognetti, F, Maraninchi, D et al. (2005) Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Onco.l 23: 4265–74.CrossRefGoogle ScholarPubMed
O'Shaughnessy, JA, Vukelja, S, Marsland, T et al. (2004) Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 5: 142–7.CrossRefGoogle ScholarPubMed
Slamon, DJ, Leyland-Jones, B, Shak, S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344: 783–92.CrossRefGoogle Scholar
Minckwitz, G, du Bois, A, Schmidt, M, et al. (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German breast group 26/breast international group 03-05 study. J Clin Oncol. 27:1999–2006.Google Scholar
Pritchard, KI, Messersmith, H, Elavathil, L et al. (2008) HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. 26: 736–44.CrossRefGoogle ScholarPubMed
Bartlett, JM, Munro, A, Cameron, DA et al. (2008) Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol. 26: 5027–35.CrossRefGoogle ScholarPubMed
Seidman, A, Hudis, C, Pierri, MK et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 20: 1215–21.CrossRefGoogle ScholarPubMed
Dang, CT, Dannenberg, AJ, Subbaramaiah, K et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 10: 4062–7. (2004)CrossRefGoogle ScholarPubMed
Kaufman, B, Mackey, J, Clemens, M (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormonedependent metastatic breast cancer (MBC). Ann Oncol. 17 Suppl 17: LBA2.Google Scholar
Geyer, CE, Forster, J, Lindquist, D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355: 2733–43.CrossRefGoogle ScholarPubMed
Johnston, S, Trudeau, M, Kaufman, B et al. (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. 26: 1066–72.CrossRefGoogle ScholarPubMed
Burstein, HJ, Sun, Y, Tan, AR et al. (2008) Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. San Antonio Breast Cancer Symposium: Abstract 37.
Albanell, J, Montagut, C, Jones, ET et al. (2008) A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res. 14: 2726–31.CrossRefGoogle ScholarPubMed
Attard, G, Kitzen, J, Blagden, SP et al. (2007) A Phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer. 97: 1338–43.CrossRefGoogle ScholarPubMed
Kiewe, P, Hasmuller, S, Kahlert, S et al. (2006) Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 12: 3085–91.CrossRefGoogle ScholarPubMed
Beeram, M, Burris H, A., Modi, S et al. (2008) A Phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC) ASCO Meeting Abstracts: Abstract 1028.
Holden, S, Beeram, M, Krop, I et al. (2008) A Phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC) ASCO Meeting Abstracts: Abstract 1029.
Modi, S, Stopeck, AT, Gordon, MS et al. (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a Phase I dose-escalation study. J Clin Oncol. 25: 5410–7.CrossRefGoogle ScholarPubMed
Egorin, M, Belani, C, Remick, S et al. (2006) Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG, NSC 707545) in patients with advanced solid tumors. J Clin Oncol. 24: 18S Abstract 3021.Google Scholar
Miller, KD, Chap, LI, Holmes, FA et al. (2005) Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 23: 792–9.CrossRefGoogle ScholarPubMed
Miller, K, Wang, M, Gralow, J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357: 2666–76.CrossRefGoogle ScholarPubMed
Miles, D, Chan, A, Romieu, G (2008) Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol. 26: LBA1011.CrossRefGoogle Scholar
Ince, WL, Jubb, AM, Holden, SN et al. (2005) Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 97: 981–9.CrossRefGoogle ScholarPubMed
Jubb, AM, Hurwitz, HI, Bai, W et al. (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 24: 217–27.CrossRefGoogle ScholarPubMed
Schneider, BP, Wang, M, Radovich, M et al. (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 26: 4672–8.CrossRefGoogle Scholar
Doane, AS, Danso, M, Lal, P et al. (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 25: 3994–4008.CrossRefGoogle Scholar
Isola, JJ (1993) Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 170: 31–5.CrossRefGoogle ScholarPubMed
Agoff, SN, Swanson, PE, Linden, H et al. (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 120: 725–31.CrossRefGoogle ScholarPubMed
Finn, RS (2008) Targeting Src in breast cancer. Ann Oncol 19:1379–86, 2008CrossRefGoogle ScholarPubMed
Finn, RS, Dering, J, Ginther, C et al. (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 105(3): 319–26.CrossRefGoogle ScholarPubMed
Drew, Y, Calvert, H (2008) The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann NY Acad Sci. 1138: 136–45.CrossRefGoogle ScholarPubMed
Hamaoka, T, Madewell, JE, Podoloff, DA et al. (2004) Bone imaging in metastatic breast cancer. J Clin Oncol. 22: 2942–53.CrossRefGoogle ScholarPubMed
Berenson, JR, Rosen, LS, Howell, A et al. (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 91: 1191–200.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Kohno, N, Aogi, K, Minami, H et al. (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 23: 3314–21.CrossRefGoogle ScholarPubMed
Lipton, A, Theriault, RL, Hortobagyi, GN et al. (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 88: 1082–90.3.0.CO;2-Z>CrossRefGoogle ScholarPubMed
Green, JR, Muller, K, Jaeggi, KA (1994) Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 9: 745–51.CrossRefGoogle ScholarPubMed
Marx, RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 61: 1115–7.CrossRefGoogle ScholarPubMed
Thomas, ES, Gomez, HL, Li, RK et al. (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 25: 5210–7.CrossRefGoogle ScholarPubMed
Avis, NE, Smith, KW, Link, CL et al. (2006) Factors associated with participation in breast cancer treatment clinical trials. J Clin Oncol. 24: 1860–7.CrossRefGoogle ScholarPubMed
Mundy, GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2: 584–93.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×